Michael Burshtine files SEC Form 4 disclosures for Omrix Biopharmaceuticals, Inc.. They have made 2 open-market trades across 1 company since 2008, most recently 2008-01-04.
CIK 0001357554
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 2 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| OMRI | 32,665 | — |
Shares reported on the most recent Form 4, priced at the 2008-01-07 close. 1 holding could not be priced and is excluded from the total.
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.